Bone Biologics announces 1-for-8 reverse stock split effective December 20

Bone Biologics Corp

Reverse stock split at 1-for-8 ratio effective 12:01 a.m. ET on December 20, 2023.
Common stock trades post-split under symbol BBLG; warrants under BBLGW.
New CUSIP for common stock is 098070501; par value remains $0.001.
Authorized shares unchanged; fractional shares rounded up to nearest whole.
Proportionate adjustments to exercise prices and shares issuable under warrants and equity awards.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bone Biologics Corp: Filed Certificate of Amendment to effect a 1-for-8 reverse stock split of common stock, effective December 20, 2023 (effective 2023-12-20).

Change: charter amendment
Effective: 2023-12-20

Exact text from the filing

On December 14, 2023, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-8 shares, effective as of 12:01 a.m. Eastern Time on December 20, 2023 (the “Reverse Stock Split”).

View on SEC.gov

264 governance changes filed in the last 30 days. Browse all governance changes →

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001493152-23-045193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.